25 XP   0   0   10

Veracyte Inc
Buy, Hold or Sell?

Let's analyse Veracyte together

PenkeI guess you are interested in Veracyte Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Veracyte Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Veracyte Inc

I send you an email if I find something interesting about Veracyte Inc.

Quick analysis of Veracyte (30 sec.)










What can you expect buying and holding a share of Veracyte? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$13.91
Expected worth in 1 year
$13.49
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-0.41
Return On Investment
-2.2%

For what price can you sell your share?

Current Price per Share
$19.20
Expected price per share
$14.92 - $21.86
How sure are you?
50%

1. Valuation of Veracyte (5 min.)




Live pricePrice per Share (EOD)

$19.20

Intrinsic Value Per Share

$1.51 - $8.59

Total Value Per Share

$15.42 - $22.50

2. Growth of Veracyte (5 min.)




Is Veracyte growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$1b-$10.7m-1.0%

How much money is Veracyte making?

Current yearPrevious yearGrowGrow %
Making money-$17.9m-$9.1m-$8.8m-49.2%
Net Profit Margin-19.5%-12.7%--

How much money comes from the company's main activities?

3. Financial Health of Veracyte (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#54 / 1016

Most Revenue
#108 / 1016

Most Profit
#676 / 1016

Most Efficient
#497 / 1016

What can you expect buying and holding a share of Veracyte? (5 min.)

Welcome investor! Veracyte's management wants to use your money to grow the business. In return you get a share of Veracyte.

What can you expect buying and holding a share of Veracyte?

First you should know what it really means to hold a share of Veracyte. And how you can make/lose money.

Speculation

The Price per Share of Veracyte is $19.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Veracyte.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Veracyte, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $13.91. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Veracyte.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.38-2.0%-0.25-1.3%-0.12-0.6%-0.16-0.8%-0.13-0.7%
Usd Book Value Change Per Share-0.13-0.7%-0.10-0.5%-0.07-0.4%0.643.3%0.331.7%
Usd Dividend Per Share0.000.0%0.000.0%0.010.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.13-0.7%-0.10-0.5%-0.06-0.3%0.643.4%0.331.7%
Usd Price Per Share27.51-24.40-21.95-30.19-19.59-
Price to Earnings Ratio-18.25--35.25--56.63--105.08--65.59-
Price-to-Total Gains Ratio-207.40-330.22--3.20--102.13--16.23-
Price to Book Ratio1.98-1.72-1.53-5.29-10.09-
Price-to-Total Gains Ratio-207.40-330.22--3.20--102.13--16.23-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share19.2
Number of shares52
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.100.64
Usd Total Gains Per Share-0.100.64
Gains per Quarter (52 shares)-5.3933.47
Gains per Year (52 shares)-21.54133.88
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-22-320134124
20-43-541267258
30-65-761401392
40-86-981534526
50-108-1201668660
60-129-1422802794
70-151-1642935928
80-172-186210691062
90-194-208312021196
100-215-230313361330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.046.01.00.0%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%11.09.00.055.0%16.024.00.040.0%19.026.02.040.4%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.045.04.3%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%11.09.00.055.0%16.024.00.040.0%19.026.02.040.4%

Fundamentals of Veracyte

About Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-12 21:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Veracyte Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Veracyte earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Veracyte to the Biotechnology industry mean.
  • A Net Profit Margin of -28.8% means that $-0.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Veracyte Inc:

  • The MRQ is -28.8%. The company is making a huge loss. -2
  • The TTM is -19.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-28.8%TTM-19.5%-9.3%
TTM-19.5%YOY-12.7%-6.8%
TTM-19.5%5Y-23.4%+3.9%
5Y-23.4%10Y-38.4%+15.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.8%-197.2%+168.4%
TTM-19.5%-210.4%+190.9%
YOY-12.7%-279.3%+266.6%
5Y-23.4%-436.8%+413.4%
10Y-38.4%-599.3%+560.9%
1.1.2. Return on Assets

Shows how efficient Veracyte is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Veracyte to the Biotechnology industry mean.
  • -2.5% Return on Assets means that Veracyte generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Veracyte Inc:

  • The MRQ is -2.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.5%TTM-1.6%-0.9%
TTM-1.6%YOY-0.8%-0.8%
TTM-1.6%5Y-1.7%+0.1%
5Y-1.7%10Y-5.7%+4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.5%-13.6%+11.1%
TTM-1.6%-12.9%+11.3%
YOY-0.8%-11.9%+11.1%
5Y-1.7%-14.2%+12.5%
10Y-5.7%-16.2%+10.5%
1.1.3. Return on Equity

Shows how efficient Veracyte is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Veracyte to the Biotechnology industry mean.
  • -2.7% Return on Equity means Veracyte generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Veracyte Inc:

  • The MRQ is -2.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.7%TTM-1.7%-1.0%
TTM-1.7%YOY-0.8%-0.9%
TTM-1.7%5Y-1.9%+0.2%
5Y-1.9%10Y-9.6%+7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.7%-17.0%+14.3%
TTM-1.7%-16.1%+14.4%
YOY-0.8%-15.4%+14.6%
5Y-1.9%-20.0%+18.1%
10Y-9.6%-21.1%+11.5%

1.2. Operating Efficiency of Veracyte Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Veracyte is operating .

  • Measures how much profit Veracyte makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Veracyte to the Biotechnology industry mean.
  • An Operating Margin of -1.5% means the company generated $-0.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Veracyte Inc:

  • The MRQ is -1.5%. The company is operating very inefficient. -2
  • The TTM is 4.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM4.8%-6.2%
TTM4.8%YOY-13.9%+18.7%
TTM4.8%5Y-19.4%+24.2%
5Y-19.4%10Y-35.1%+15.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%-286.1%+284.6%
TTM4.8%-224.4%+229.2%
YOY-13.9%-288.4%+274.5%
5Y-19.4%-475.2%+455.8%
10Y-35.1%-624.7%+589.6%
1.2.2. Operating Ratio

Measures how efficient Veracyte is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.01 means that the operating costs are $1.01 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Veracyte Inc:

  • The MRQ is 1.015. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.146. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.015TTM1.146-0.131
TTM1.146YOY1.139+0.007
TTM1.1465Y1.238-0.092
5Y1.23810Y1.374-0.136
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0152.997-1.982
TTM1.1463.247-2.101
YOY1.1393.766-2.627
5Y1.2385.675-4.437
10Y1.3747.857-6.483

1.3. Liquidity of Veracyte Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Veracyte is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.66 means the company has $4.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Veracyte Inc:

  • The MRQ is 4.664. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.588. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.664TTM4.588+0.076
TTM4.588YOY3.915+0.673
TTM4.5885Y9.019-4.431
5Y9.01910Y6.871+2.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6643.930+0.734
TTM4.5884.251+0.337
YOY3.9155.436-1.521
5Y9.0196.045+2.974
10Y6.8716.363+0.508
1.3.2. Quick Ratio

Measures if Veracyte is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Veracyte to the Biotechnology industry mean.
  • A Quick Ratio of 4.27 means the company can pay off $4.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Veracyte Inc:

  • The MRQ is 4.271. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.124. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.271TTM4.124+0.146
TTM4.124YOY3.580+0.545
TTM4.1245Y8.569-4.445
5Y8.56910Y6.426+2.143
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2713.629+0.642
TTM4.1244.065+0.059
YOY3.5805.397-1.817
5Y8.5695.993+2.576
10Y6.4266.277+0.149

1.4. Solvency of Veracyte Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Veracyte assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Veracyte to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Veracyte assets are financed with 8.2% credit (debt) and the remaining percentage (100% - 8.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Veracyte Inc:

  • The MRQ is 0.082. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.070. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.082TTM0.070+0.013
TTM0.070YOY0.073-0.003
TTM0.0705Y0.095-0.025
5Y0.09510Y0.254-0.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0820.332-0.250
TTM0.0700.334-0.264
YOY0.0730.268-0.195
5Y0.0950.366-0.271
10Y0.2540.390-0.136
1.4.2. Debt to Equity Ratio

Measures if Veracyte is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Veracyte to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.0% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Veracyte Inc:

  • The MRQ is 0.090. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.075. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.090TTM0.075+0.015
TTM0.075YOY0.079-0.004
TTM0.0755Y0.110-0.036
5Y0.11010Y0.442-0.331
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0900.381-0.291
TTM0.0750.390-0.315
YOY0.0790.334-0.255
5Y0.1100.434-0.324
10Y0.4420.466-0.024

2. Market Valuation of Veracyte Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Veracyte generates.

  • Above 15 is considered overpriced but always compare Veracyte to the Biotechnology industry mean.
  • A PE ratio of -18.25 means the investor is paying $-18.25 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Veracyte Inc:

  • The EOD is -12.735. Based on the earnings, the company is expensive. -2
  • The MRQ is -18.248. Based on the earnings, the company is expensive. -2
  • The TTM is -35.253. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.735MRQ-18.248+5.512
MRQ-18.248TTM-35.253+17.005
TTM-35.253YOY-56.632+21.379
TTM-35.2535Y-105.078+69.826
5Y-105.07810Y-65.589-39.489
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.735-2.315-10.420
MRQ-18.248-2.560-15.688
TTM-35.253-2.664-32.589
YOY-56.632-4.122-52.510
5Y-105.078-6.258-98.820
10Y-65.589-6.108-59.481
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Veracyte Inc:

  • The EOD is 27.601. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 39.546. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is -4.765. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD27.601MRQ39.546-11.946
MRQ39.546TTM-4.765+44.311
TTM-4.765YOY-15.114+10.350
TTM-4.7655Y148.311-153.075
5Y148.31110Y57.783+90.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD27.601-3.067+30.668
MRQ39.546-3.251+42.797
TTM-4.765-3.545-1.220
YOY-15.114-5.595-9.519
5Y148.311-8.315+156.626
10Y57.783-8.708+66.491
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Veracyte is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.98 means the investor is paying $1.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Veracyte Inc:

  • The EOD is 1.380. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.978. Based on the equity, the company is underpriced. +1
  • The TTM is 1.721. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.380MRQ1.978-0.597
MRQ1.978TTM1.721+0.257
TTM1.721YOY1.529+0.192
TTM1.7215Y5.286-3.566
5Y5.28610Y10.085-4.799
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3801.905-0.525
MRQ1.9782.111-0.133
TTM1.7212.095-0.374
YOY1.5292.836-1.307
5Y5.2863.443+1.843
10Y10.0853.794+6.291
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Veracyte Inc.

3.1. Institutions holding Veracyte Inc

Institutions are holding 97.484% of the shares of Veracyte Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31ARK Investment Management LLC10.19821.24697655603620110.8166
2023-12-31BlackRock Inc9.54050.00571618662723763.9535
2023-12-31Vanguard Group Inc9.48240.00437118211526990.7459
2023-12-31Wellington Management Company LLP9.41610.036370684355710.0081
2023-12-31Dimensional Fund Advisors, Inc.4.49290.027133727031610735.0153
2023-12-31Artisan Partners Limited Partnership4.28640.13633217728-193394-5.6695
2023-12-31State Street Corporation4.14110.00423108639-142653-4.3876
2023-12-31Nikko Asset Management Americas Inc4.13580.8213104676-68900-2.1711
2023-12-31Sumitomo Mitsui Trust Holdings Inc4.13580.06323104676-68900-2.1711
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)3.35320.764325171402062818.9266
2023-12-31Goldman Sachs Group Inc3.23960.0062431892112573086.1861
2023-12-31Champlain Investment Partners, LLC2.9150.35692188260-115940-5.0317
2023-12-31Geode Capital Management, LLC2.15370.00471616765736244.771
2023-12-31GW&K Investment Management, LLC1.88530.363141523718361614.9085
2023-12-31Nuveen Asset Management, LLC1.36180.0091022279-75003-6.8353
2023-12-31Northern Trust Corp1.30520.0049979797-2531-0.2577
2023-12-31Fisher Asset Management, LLC1.16580.0127875161-130268-12.9565
2023-12-31Granite Investment Partners, LLC1.16330.934887325174810.8641
2023-12-31Bank of America Corp1.11830.0023839464680338.8191
2023-12-31New York State Common Retirement Fund1.11560.0319837467-69814-7.6949
Total 80.6064.834860509250+1346092+2.2%

3.2. Funds holding Veracyte Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28ARK Innovation ETF5.54991.18764166193-24174-0.5769
2024-03-31ARK Disruptive Innovation Full Composite5.53561.18594155449-208677-4.7816
2023-12-31Vanguard Explorer Inv4.67390.451435085671480454.4054
2024-03-28SPDR® S&P Biotech ETF3.42460.75442570744324401.278
2024-02-29Vanguard Total Stock Mkt Idx Inv3.02880.00352273673-9700-0.4248
2024-02-29Nikko AM ARK Disruptive Innovation A USD3.0231.727322692883330.0147
2024-02-29Champlain Small Company Fund, LLC2.73371.0434205209540749524.7778
2024-03-31ARK Genomic Revolution2.59712.68821949575-317453-14.003
2024-03-28ARK Genomic Revolution ETF2.59012.6894194434900
2024-02-29Vanguard Small Cap Index2.5080.03161882665174920.9378
2024-03-28iShares Russell 2000 ETF2.38020.06051786729140960.7952
2023-12-31Artisan Small Cap Investor2.27822.79571710182-93741-5.1965
2023-12-31Artisan U.S. Small-Cap Growth2.27822.78191710182-93741-5.1965
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.42110.024610667557450.0699
2024-02-29Vanguard Small Cap Growth Index Inv1.40760.07131056681175331.6872
2023-12-31Champlain Small Company Adv1.18560.9998890000-65000-6.8063
2024-01-31Fidelity Small Cap Index0.98130.0743736670115881.5982
2024-03-28iShares Russell 2000 Value ETF0.91510.1214686916-436-0.0634
2024-03-31ARK Next Generation Internet0.86580.821649939-67936-9.4635
2024-03-28ARK Next Generation Internet ETF0.86580.82264993992641.446
Total 50.243620.335237716591-221827-0.6%

3.3. Insider Transactions

Insiders are holding 1.157% of the shares of Veracyte Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-01Karin EasthamSELL1000021.65
2023-07-18John L BishopSELL1000030.5
2023-06-16Muna BhanjiSELL589326.44
2023-05-30Muna BhanjiSELL153925.91
2023-04-14Bonnie H AndersonSELL3400022.04

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Veracyte Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.133-0.104-22%-0.071-46%0.642-121%0.329-140%
Book Value Per Share--13.90914.194-2%14.337-3%9.855+41%5.246+165%
Current Ratio--4.6644.588+2%3.915+19%9.019-48%6.871-32%
Debt To Asset Ratio--0.0820.070+18%0.073+13%0.095-13%0.254-68%
Debt To Equity Ratio--0.0900.075+20%0.079+14%0.110-19%0.442-80%
Dividend Per Share----0%0.007-100%0.001-100%0.001-100%
Eps---0.377-0.248-34%-0.122-68%-0.156-59%-0.127-66%
Free Cash Flow Per Share--0.1740.114+52%-0.003+102%-0.015+109%-0.053+130%
Free Cash Flow To Equity Per Share--0.1830.124+48%0.008+2110%0.607-70%0.308-41%
Gross Profit Margin--1.2513.184-61%4.020-69%4.231-70%3.177-61%
Intrinsic Value_10Y_max--8.589--------
Intrinsic Value_10Y_min--1.507--------
Intrinsic Value_1Y_max--0.110--------
Intrinsic Value_1Y_min---0.150--------
Intrinsic Value_3Y_max--0.904--------
Intrinsic Value_3Y_min---0.193--------
Intrinsic Value_5Y_max--2.386--------
Intrinsic Value_5Y_min--0.047--------
Market Cap1441301760.000-43%2065115178.0001831841989.500+13%1647738210.000+25%2266597153.200-9%1470334231.650+40%
Net Profit Margin---0.288-0.195-32%-0.127-56%-0.234-19%-0.384+33%
Operating Margin---0.0150.048-130%-0.139+856%-0.194+1240%-0.351+2322%
Operating Ratio--1.0151.146-11%1.139-11%1.238-18%1.374-26%
Pb Ratio1.380-43%1.9781.721+15%1.529+29%5.286-63%10.085-80%
Pe Ratio-12.735+30%-18.248-35.253+93%-56.632+210%-105.078+476%-65.589+259%
Price Per Share19.200-43%27.51024.403+13%21.950+25%30.194-9%19.587+40%
Price To Free Cash Flow Ratio27.601-43%39.546-4.765+112%-15.114+138%148.311-73%57.783-32%
Price To Total Gains Ratio-144.753+30%-207.403330.216-163%-3.196-98%-102.127-51%-16.228-92%
Quick Ratio--4.2714.124+4%3.580+19%8.569-50%6.426-34%
Return On Assets---0.025-0.016-36%-0.008-68%-0.017-33%-0.057+128%
Return On Equity---0.027-0.017-37%-0.008-69%-0.019-31%-0.096+255%
Total Gains Per Share---0.133-0.104-22%-0.064-52%0.644-121%0.330-140%
Usd Book Value--1044102000.0001065534500.000-2%1076270250.000-3%739761900.000+41%393807650.000+165%
Usd Book Value Change Per Share---0.133-0.104-22%-0.071-46%0.642-121%0.329-140%
Usd Book Value Per Share--13.90914.194-2%14.337-3%9.855+41%5.246+165%
Usd Dividend Per Share----0%0.007-100%0.001-100%0.001-100%
Usd Eps---0.377-0.248-34%-0.122-68%-0.156-59%-0.127-66%
Usd Free Cash Flow--13055000.0008565250.000+52%-253500.000+102%-1114300.000+109%-3958225.000+130%
Usd Free Cash Flow Per Share--0.1740.114+52%-0.003+102%-0.015+109%-0.053+130%
Usd Free Cash Flow To Equity Per Share--0.1830.124+48%0.008+2110%0.607-70%0.308-41%
Usd Market Cap1441301760.000-43%2065115178.0001831841989.500+13%1647738210.000+25%2266597153.200-9%1470334231.650+40%
Usd Price Per Share19.200-43%27.51024.403+13%21.950+25%30.194-9%19.587+40%
Usd Profit---28293000.000-17999250.000-36%-9140000.000-68%-11581400.000-59%-9501625.000-66%
Usd Revenue--98199000.00090262750.000+9%74134000.000+32%55747600.000+76%35792275.000+174%
Usd Total Gains Per Share---0.133-0.104-22%-0.064-52%0.644-121%0.330-140%
 EOD+4 -4MRQTTM+12 -22YOY+13 -235Y+14 -2210Y+19 -17

4.2. Fundamental Score

Let's check the fundamental score of Veracyte Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-12.735
Price to Book Ratio (EOD)Between0-11.380
Net Profit Margin (MRQ)Greater than0-0.288
Operating Margin (MRQ)Greater than0-0.015
Quick Ratio (MRQ)Greater than14.271
Current Ratio (MRQ)Greater than14.664
Debt to Asset Ratio (MRQ)Less than10.082
Debt to Equity Ratio (MRQ)Less than10.090
Return on Equity (MRQ)Greater than0.15-0.027
Return on Assets (MRQ)Greater than0.05-0.025
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Veracyte Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.718
Ma 20Greater thanMa 5020.596
Ma 50Greater thanMa 10022.322
Ma 100Greater thanMa 20024.439
OpenGreater thanClose18.750
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,137,821
Total Liabilities93,719
Total Stockholder Equity1,044,102
 As reported
Total Liabilities 93,719
Total Stockholder Equity+ 1,044,102
Total Assets = 1,137,821

Assets

Total Assets1,137,821
Total Current Assets285,621
Long-term Assets852,200
Total Current Assets
Cash And Cash Equivalents 216,454
Net Receivables 45,078
Inventory 16,128
Other Current Assets 7,961
Total Current Assets  (as reported)285,621
Total Current Assets  (calculated)285,621
+/-0
Long-term Assets
Property Plant Equipment 30,861
Goodwill 702,984
Intangible Assets 88,593
Long-term Assets Other 5,971
Long-term Assets  (as reported)852,200
Long-term Assets  (calculated)828,409
+/- 23,791

Liabilities & Shareholders' Equity

Total Current Liabilities61,241
Long-term Liabilities32,478
Total Stockholder Equity1,044,102
Total Current Liabilities
Short-term Debt 5,105
Accounts payable 12,943
Other Current Liabilities 41,185
Total Current Liabilities  (as reported)61,241
Total Current Liabilities  (calculated)59,233
+/- 2,008
Long-term Liabilities
Capital Lease Obligations 12,630
Long-term Liabilities Other 1,304
Long-term Liabilities  (as reported)32,478
Long-term Liabilities  (calculated)13,934
+/- 18,544
Total Stockholder Equity
Common Stock73
Retained Earnings -468,121
Accumulated Other Comprehensive Income -24,018
Other Stockholders Equity 1,536,168
Total Stockholder Equity (as reported)1,044,102
Total Stockholder Equity (calculated)1,044,102
+/-0
Other
Capital Stock73
Cash and Short Term Investments 216,454
Common Stock Shares Outstanding 73,107
Current Deferred Revenue2,008
Liabilities and Stockholders Equity 1,137,821
Net Debt -203,824
Net Invested Capital 1,044,102
Net Working Capital 224,380
Property Plant and Equipment Gross 63,721
Short Long Term Debt Total 12,630



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302011-12-31
> Total Assets 
10,451
0
19,067
0
27,159
23,571
79,630
72,454
67,750
71,814
64,839
55,060
82,503
80,853
75,285
84,267
74,832
69,650
101,034
92,606
88,347
83,659
78,669
71,190
65,461
119,077
120,638
123,537
252,377
260,307
275,212
267,100
256,737
454,151
457,163
1,025,136
1,027,435
1,186,356
1,187,825
1,173,589
1,187,825
1,125,957
1,156,422
1,157,119
1,161,114
1,124,943
1,137,821
1,137,8211,124,9431,161,1141,157,1191,156,4221,125,9571,187,8251,173,5891,187,8251,186,3561,027,4351,025,136457,163454,151256,737267,100275,212260,307252,377123,537120,638119,07765,46171,19078,66983,65988,34792,606101,03469,65074,83284,26775,28580,85382,50355,06064,83971,81467,75072,45479,63023,57127,159019,067010,451
   > Total Current Assets 
0
0
16,381
0
23,842
20,470
76,407
69,163
64,178
50,668
43,348
33,691
60,714
57,331
47,933
56,194
47,397
42,952
73,627
66,295
62,860
58,207
53,928
47,049
41,635
95,374
96,952
90,616
219,950
228,079
187,687
181,362
172,688
370,315
375,679
362,092
371,346
229,308
243,102
238,483
243,102
238,516
248,636
251,503
259,480
271,163
285,621
285,621271,163259,480251,503248,636238,516243,102238,483243,102229,308371,346362,092375,679370,315172,688181,362187,687228,079219,95090,61696,95295,37441,63547,04953,92858,20762,86066,29573,62742,95247,39756,19447,93357,33160,71433,69143,34850,66864,17869,16376,40720,47023,842016,38100
       Cash And Cash Equivalents 
7,566
0
14,002
0
20,683
15,426
71,220
64,237
57,998
44,002
35,014
25,798
51,045
46,116
39,084
47,456
38,993
31,699
59,219
51,506
46,463
41,195
33,891
27,152
23,758
77,846
77,995
67,841
192,647
195,662
159,317
153,132
147,450
345,080
349,364
324,062
327,545
164,029
173,197
163,615
173,197
170,112
154,247
177,890
191,142
202,463
216,454
216,454202,463191,142177,890154,247170,112173,197163,615173,197164,029327,545324,062349,364345,080147,450153,132159,317195,662192,64767,84177,99577,84623,75827,15233,89141,19546,46351,50659,21931,69938,99347,45639,08446,11651,04525,79835,01444,00257,99864,23771,22015,42620,683014,00207,566
       Short-term Investments 
0
0
50
0
0
0
0
0
0
100
70
118
118
118
118
238
120
120
120
120
120
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,964
0
24,605
0
0
0
0
000024,60503,9640000000000000000000120120120120120238118118118118701000000005000
       Net Receivables 
0
0
569
0
991
714
1,143
1,191
1,430
1,180
3,050
2,564
3,586
3,520
3,503
3,230
3,387
6,312
8,756
9,125
11,027
11,635
12,716
13,198
13,006
12,262
13,168
16,615
19,626
23,613
19,329
19,091
15,306
17,629
18,461
27,877
31,864
40,309
41,461
42,481
41,461
40,068
44,021
45,489
42,365
39,297
45,078
45,07839,29742,36545,48944,02140,06841,46142,48141,46140,30931,86427,87718,46117,62915,30619,09119,32923,61319,62616,61513,16812,26213,00613,19812,71611,63511,0279,1258,7566,3123,3873,2303,5033,5203,5862,5643,0501,1801,4301,1911,143714991056900
       Inventory 
279
0
1,050
0
770
1,392
2,567
2,721
3,300
3,350
3,696
3,732
3,976
3,984
3,767
3,652
3,502
3,416
3,475
3,443
3,317
3,760
5,324
4,557
3,049
3,463
3,402
3,768
5,104
6,608
6,806
6,094
7,041
4,456
4,657
6,308
6,674
9,824
11,225
12,372
11,225
13,798
14,294
13,306
11,572
15,887
16,128
16,12815,88711,57213,30614,29413,79811,22512,37211,2259,8246,6746,3084,6574,4567,0416,0946,8066,6085,1043,7683,4023,4633,0494,5575,3243,7603,3173,4433,4753,4163,5023,6523,7673,9843,9763,7323,6963,3503,3002,7212,5671,39277001,0500279
   > Long-term Assets 
0
0
2,686
0
3,317
3,101
3,223
3,291
3,572
21,146
21,491
21,369
21,789
23,522
27,352
28,073
27,435
26,698
27,407
26,311
25,487
25,452
24,741
24,141
23,826
23,703
23,686
32,921
32,427
32,228
87,525
85,738
84,049
83,836
81,484
663,044
656,089
957,048
944,723
935,106
944,723
887,441
907,786
905,616
901,634
853,780
852,200
852,200853,780901,634905,616907,786887,441944,723935,106944,723957,048656,089663,04481,48483,83684,04985,73887,52532,22832,42732,92123,68623,70323,82624,14124,74125,45225,48726,31127,40726,69827,43528,07327,35223,52221,78921,36921,49121,1463,5723,2913,2233,1013,31702,68600
       Property Plant Equipment 
1,687
0
2,446
0
3,025
2,826
2,952
3,028
3,312
3,792
4,161
4,132
4,211
6,200
10,314
11,272
10,937
10,435
11,480
10,657
10,093
10,281
9,688
9,215
9,035
8,939
8,940
18,479
18,239
18,140
17,741
17,364
16,979
17,008
16,833
25,748
26,372
30,869
31,141
31,962
31,141
31,122
30,862
29,380
30,965
30,585
30,861
30,86130,58530,96529,38030,86231,12231,14131,96231,14130,86926,37225,74816,83317,00816,97917,36417,74118,14018,23918,4798,9408,9399,0359,2159,68810,28110,09310,65711,48010,43510,93711,27210,3146,2004,2114,1324,1613,7923,3123,0282,9522,8263,02502,44601,687
       Goodwill 
0
0
0
0
0
0
0
0
0
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
1,057
2,725
2,725
2,725
2,725
2,725
474,838
471,764
714,273
707,904
704,368
707,904
676,885
695,891
699,718
698,920
693,176
702,984
702,984693,176698,920699,718695,891676,885707,904704,368707,904714,273471,764474,8382,7252,7252,7252,7252,7251,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,0571,057000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
16,000
16,000
16,000
15,733
15,467
15,200
14,933
14,666
14,400
14,133
13,867
13,600
13,333
13,067
12,800
12,533
12,267
12,000
11,733
11,467
11,200
65,019
63,744
62,471
61,197
59,924
159,423
155,700
209,521
202,731
196,228
202,731
176,542
174,866
170,226
164,744
123,567
88,593
88,593123,567164,744170,226174,866176,542202,731196,228202,731209,521155,700159,42359,92461,19762,47163,74465,01911,20011,46711,73312,00012,26712,53312,80013,06713,33313,60013,86714,13314,40014,66614,93315,20015,46715,73316,00016,00016,000000000000
       Long-term Assets Other 
0
0
240
0
292
275
271
263
260
297
273
180
788
798
781
811
775
806
737
730
737
781
929
1,069
1,201
1,440
1,689
1,652
1,664
1,831
2,040
1,905
1,874
2,906
2,002
3,035
2,253
2,385
2,947
2,548
2,947
2,892
-26,800
6,292
7,005
6,452
5,971
5,9716,4527,0056,292-26,8002,8922,9472,5482,9472,3852,2533,0352,0022,9061,8741,9052,0401,8311,6641,6521,6891,4401,2011,069929781737730737806775811781798788180273297260263271275292024000
> Total Liabilities 
1,921
0
14,166
0
18,747
21,124
23,187
22,164
22,725
23,531
23,465
19,981
17,415
23,042
24,033
40,961
41,079
39,645
41,453
39,256
40,503
40,843
41,444
41,182
39,655
39,660
40,883
39,765
28,137
29,283
35,757
36,678
30,590
31,426
35,931
50,905
56,258
79,276
91,311
88,399
91,311
77,780
81,222
75,860
78,396
70,884
93,719
93,71970,88478,39675,86081,22277,78091,31188,39991,31179,27656,25850,90535,93131,42630,59036,67835,75729,28328,13739,76540,88339,66039,65541,18241,44440,84340,50339,25641,45339,64541,07940,96124,03323,04217,41519,98123,46523,53122,72522,16423,18721,12418,747014,16601,921
   > Total Current Liabilities 
1,886
0
8,991
0
9,793
12,520
15,388
15,448
17,107
18,010
17,145
14,147
11,802
15,432
14,722
11,879
11,842
10,270
11,534
9,411
10,799
11,219
12,028
11,839
10,391
10,436
13,059
14,329
15,321
16,772
17,469
19,194
13,105
13,919
16,781
32,709
36,105
50,037
64,151
62,543
64,151
58,352
62,614
55,993
58,151
57,260
61,241
61,24157,26058,15155,99362,61458,35264,15162,54364,15150,03736,10532,70916,78113,91913,10519,19417,46916,77215,32114,32913,05910,43610,39111,83912,02811,21910,7999,41111,53410,27011,84211,87914,72215,43211,80214,14717,14518,01017,10715,44815,38812,5209,79308,99101,886
       Short-term Debt 
0
0
0
0
0
0
0
467
940
1,420
4,923
0
0
0
4,990
0
0
0
25,517
25,472
25,427
25,379
25,246
25,249
25,259
0
1,357
1,477
1,440
1,444
1,407
1,450
1,495
1,542
1,589
2,878
2,936
3,465
4,757
4,928
1,127
5,145
4,070
4,076
4,973
5,007
5,105
5,1055,0074,9734,0764,0705,1451,1274,9284,7573,4652,9362,8781,5891,5421,4951,4501,4071,4441,4401,4771,357025,25925,24925,24625,37925,42725,47225,5170004,9900004,9231,4209404670000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
4,923
0
0
0
4,990
0
0
0
25,517
25,472
25,427
25,379
25,246
25,249
25,259
0
1,357
1,244
0
0
0
0
0
0
0
0
0
0
1,127
1,079
1,133
1,187
0
0
0
0
0
000001,1871,1331,0791,12700000000001,2441,357025,25925,24925,24625,37925,42725,47225,5170004,9900004,9230000000000
       Accounts payable 
550
0
1,888
0
1,906
5,604
5,294
7,214
8,539
8,587
7,397
6,854
2,688
6,644
5,085
4,340
2,705
3,081
2,424
2,611
2,349
3,161
3,853
3,356
1,962
1,175
2,516
4,064
4,061
5,568
2,328
7,665
2,224
1,932
3,116
7,137
8,472
11,201
12,360
11,273
12,360
11,114
11,911
15,655
12,895
12,531
12,943
12,94312,53112,89515,65511,91111,11412,36011,27312,36011,2018,4727,1373,1161,9322,2247,6652,3285,5684,0614,0642,5161,1751,9623,3563,8533,1612,3492,6112,4243,0812,7054,3405,0856,6442,6886,8547,3978,5878,5397,2145,2945,6041,90601,8880550
       Other Current Liabilities 
1,336
0
7,103
0
7,887
6,916
10,094
7,767
7,628
8,003
9,748
7,293
9,114
8,788
9,637
7,539
9,137
7,189
9,110
6,800
8,450
8,058
8,175
8,483
8,429
9,261
9,186
8,788
9,820
9,760
13,734
10,079
9,386
10,445
11,705
22,240
24,131
31,931
42,388
41,464
46,018
38,230
44,020
34,068
37,905
37,508
41,185
41,18537,50837,90534,06844,02038,23046,01841,46442,38831,93124,13122,24011,70510,4459,38610,07913,7349,7609,8208,7889,1869,2618,4298,4838,1758,0588,4506,8009,1107,1899,1377,5399,6378,7889,1147,2939,7488,0037,6287,76710,0946,9167,88707,10301,336
   > Long-term Liabilities 
0
0
5,175
0
8,954
8,604
7,799
6,716
5,618
5,521
6,320
5,834
5,613
7,610
9,311
29,082
29,237
29,375
29,919
29,845
29,704
29,624
29,416
29,343
29,264
29,224
27,824
25,436
12,816
12,511
18,288
17,484
17,485
17,507
19,150
18,196
20,153
29,239
27,160
25,856
27,160
19,428
18,608
19,867
20,245
13,624
32,478
32,47813,62420,24519,86718,60819,42827,16025,85627,16029,23920,15318,19619,15017,50717,48517,48418,28812,51112,81625,43627,82429,22429,26429,34329,41629,62429,70429,84529,91929,37529,23729,0829,3117,6105,6135,8346,3205,5215,6186,7167,7998,6048,95405,17500
       Long term Debt Total 
0
0
0
0
0
4,863
4,899
4,467
4,031
3,587
4,923
4,949
4,975
5,002
5,028
24,452
24,671
24,891
25,517
25,472
25,427
25,379
25,246
25,249
25,259
25,271
23,925
12,854
585
639
694
748
0
0
810
0
0
0
0
0
0
0
0
0
0
0
0
0000000000008100074869463958512,85423,92525,27125,25925,24925,24625,37925,42725,47225,51724,89124,67124,4525,0285,0024,9754,9494,9233,5874,0314,4674,8994,86300000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
-467
-940
-1,420
-4,923
0
0
0
-4,990
0
0
0
-25,517
-25,472
-25,427
-25,379
-25,246
-25,249
-25,259
0
-1,357
12,582
12,231
11,872
11,506
11,132
10,736
10,331
9,917
14,036
13,334
14,236
12,969
12,406
15,332
10,340
10,648
9,709
9,891
8,720
7,525
7,5258,7209,8919,70910,64810,34015,33212,40612,96914,23613,33414,0369,91710,33110,73611,13211,50611,87212,23112,582-1,3570-25,259-25,249-25,246-25,379-25,427-25,472-25,517000-4,990000-4,923-1,420-940-4670000000
       Warrants
0
0
0
0
0
79,022
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000079,02200000
       Long-term Liabilities Other 
0
0
0
0
0
252
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,582
12,231
11,872
17,594
16,736
5,948
16,751
18,340
16,583
4,467
21,930
7,129
19,217
14,887
13,938
14,077
14,482
5,647
1,260
1,304
1,3041,2605,64714,48214,07713,93814,88719,2177,12921,9304,46716,58318,34016,7515,94816,73617,59411,87212,23112,58200000000000000000000025200000
       Deferred Long Term Liability 
0
0
0
0
0
3,489
2,900
2,249
1,587
1,934
1,397
885
638
2,608
4,283
4,630
4,566
4,484
4,402
4,373
4,277
4,245
4,170
4,094
4,005
3,953
3,899
0
0
0
0
0
0
0
0
750
773
6,234
5,592
4,983
4,605
4,342
4,531
4,594
4,707
0
0
004,7074,5944,5314,3424,6054,9835,5926,234773750000000003,8993,9534,0054,0944,1704,2454,2774,3734,4024,4844,5664,6304,2832,6086388851,3971,9341,5872,2492,9003,48900000
> Total Stockholder Equity
8,530
0
4,901
0
8,412
2,447
56,443
50,290
45,025
48,283
41,374
35,079
65,088
57,811
51,252
43,306
33,753
30,005
59,581
53,350
47,844
42,816
37,225
30,008
25,806
79,417
79,755
83,772
224,240
231,024
239,455
230,422
226,147
422,725
421,232
974,231
971,177
1,107,080
1,096,514
1,085,190
1,096,514
1,048,177
1,075,200
1,081,259
1,082,718
1,054,059
1,044,102
1,044,1021,054,0591,082,7181,081,2591,075,2001,048,1771,096,5141,085,1901,096,5141,107,080971,177974,231421,232422,725226,147230,422239,455231,024224,24083,77279,75579,41725,80630,00837,22542,81647,84453,35059,58130,00533,75343,30651,25257,81165,08835,07941,37448,28345,02550,29056,4432,4478,41204,90108,530
   Common Stock
1
0
1
0
16
1
21
21
21
22
23
23
27
27
28
28
28
28
34
34
34
34
34
34
34
41
41
42
48
49
50
50
50
58
58
67
67
71
71
71
72
72
72
72
73
73
73
73737372727272717171676758585050504948424141343434343434342828282827272323222121211160101
   Retained Earnings Total Equity00-410,210-401,808-393,717-389,873-381,150-371,618-357,157-346,629-332,500-323,462-281,594-273,550-269,426-258,401-246,685-239,227-238,497-236,003-234,100-230,981-226,512-220,264-211,100-202,648-195,599-188,301-180,084-175,681-170,044-158,801-148,726-140,713-131,768-122,632-115,022-106,880-98,978-92,323-85,649-79,75700000
   Accumulated Other Comprehensive Income -24,018-34,197-27,783-26,866-31,346-54,066-38,050-20,681-15,083-8,140000000-14,080000-12,006000-9,30500-6,836-6,83600-5,440-5,44000-3,990-3,99000-2,815-2,815000-1,81600
   Capital Surplus 
0
0
0
0
0
3,181
142,071
142,592
143,982
155,141
156,373
157,688
196,829
198,497
199,950
202,079
203,769
205,658
239,631
241,617
243,409
245,430
248,278
250,238
252,284
310,357
313,800
319,733
462,689
470,202
486,090
488,773
495,523
696,217
702,768
1,297,626
1,303,610
1,461,778
1,468,683
1,477,418
1,483,279
1,492,044
1,500,191
1,509,861
1,520,638
0
0
001,520,6381,509,8611,500,1911,492,0441,483,2791,477,4181,468,6831,461,7781,303,6101,297,626702,768696,217495,523488,773486,090470,202462,689319,733313,800310,357252,284250,238248,278245,430243,409241,617239,631205,658203,769202,079199,950198,497196,829157,688156,373155,141143,982142,592142,0713,18100000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
3,413
0
81,851
3,181
144,886
142,592
143,982
155,141
160,363
157,688
196,829
198,497
205,390
202,079
203,769
205,658
246,467
241,617
243,409
245,430
257,583
250,238
252,284
310,357
325,806
319,733
462,689
470,202
500,170
488,773
495,523
696,217
702,768
1,297,626
1,303,610
1,461,778
1,187,089
1,477,418
1,096,514
1,492,044
1,500,191
1,509,861
1,082,718
1,054,059
1,536,168
1,536,1681,054,0591,082,7181,509,8611,500,1911,492,0441,096,5141,477,4181,187,0891,461,7781,303,6101,297,626702,768696,217495,523488,773500,170470,202462,689319,733325,806310,357252,284250,238257,583245,430243,409241,617246,467205,658203,769202,079205,390198,497196,829157,688160,363155,141143,982142,592144,8863,18181,85103,41300



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue361,051
Cost of Revenue-137,899
Gross Profit223,152223,152
 
Operating Income (+$)
Gross Profit223,152
Operating Expense-235,215
Operating Income-12,063-12,063
 
Operating Expense (+$)
Research Development56,366
Selling General Administrative157,628
Selling And Marketing Expenses26,604
Operating Expense235,215240,598
 
Net Interest Income (+$)
Interest Income5,666
Interest Expense-15
Other Finance Cost-3
Net Interest Income5,648
 
Pretax Income (+$)
Operating Income-12,063
Net Interest Income5,648
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-76,61252,486
EBIT - interestExpense = -12,078
-76,612
-74,389
Interest Expense15
Earnings Before Interest and Taxes (EBIT)-12,063-76,597
Earnings Before Interest and Taxes (EBITDA)15,125
 
After tax Income (+$)
Income Before Tax-76,612
Tax Provision-374
Net Income From Continuing Ops-49,955-76,986
Net Income-74,404
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses373,114
Total Other Income/Expenses Net-64,549-5,648
 

Technical Analysis of Veracyte
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Veracyte. The general trend of Veracyte is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Veracyte's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Veracyte Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 19.52 < 21.45 < 21.86.

The bearish price targets are: 19.06 > 15.00 > 14.92.

Tweet this
Veracyte Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Veracyte Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Veracyte Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Veracyte Inc. The current macd is -0.86596281.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Veracyte price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Veracyte. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Veracyte price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Veracyte Inc Daily Moving Average Convergence/Divergence (MACD) ChartVeracyte Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Veracyte Inc. The current adx is 26.44.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Veracyte shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Veracyte Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Veracyte Inc. The current sar is 20.53.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Veracyte Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Veracyte Inc. The current rsi is 34.72. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Veracyte Inc Daily Relative Strength Index (RSI) ChartVeracyte Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Veracyte Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Veracyte price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Veracyte Inc Daily Stochastic Oscillator ChartVeracyte Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Veracyte Inc. The current cci is -144.80988873.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Veracyte Inc Daily Commodity Channel Index (CCI) ChartVeracyte Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Veracyte Inc. The current cmo is -33.4800775.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Veracyte Inc Daily Chande Momentum Oscillator (CMO) ChartVeracyte Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Veracyte Inc. The current willr is -83.04597701.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Veracyte Inc Daily Williams %R ChartVeracyte Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Veracyte Inc.

Veracyte Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Veracyte Inc. The current atr is 0.86261456.

Veracyte Inc Daily Average True Range (ATR) ChartVeracyte Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Veracyte Inc. The current obv is 1,360,702.

Veracyte Inc Daily On-Balance Volume (OBV) ChartVeracyte Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Veracyte Inc. The current mfi is 33.81.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Veracyte Inc Daily Money Flow Index (MFI) ChartVeracyte Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Veracyte Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Veracyte Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Veracyte Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.718
Ma 20Greater thanMa 5020.596
Ma 50Greater thanMa 10022.322
Ma 100Greater thanMa 20024.439
OpenGreater thanClose18.750
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Veracyte with someone you think should read this too:
  • Are you bullish or bearish on Veracyte? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Veracyte? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Veracyte Inc

I send you an email if I find something interesting about Veracyte Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Veracyte Inc.

Receive notifications about Veracyte Inc in your mailbox!